These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23315316)

  • 1. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
    Matthews GV; Seaberg EC; Avihingsanon A; Bowden S; Dore GJ; Lewin SR; Sasadeusz J; Revill PA; Littlejohn M; Hoy JF; Finlayson R; Ruxrungtham K; Saulynas M; Locarnini S; Thio CL
    Clin Infect Dis; 2013 May; 56(9):e87-94. PubMed ID: 23315316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
    Boyd A; Gozlan J; Maylin S; Delaugerre C; Peytavin G; Girard PM; Zoulim F; Lacombe K
    Hepatology; 2014 Aug; 60(2):497-507. PubMed ID: 24752996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
    Miailhes P; Maynard-Muet M; Lebossé F; Carrat F; Bouix C; Lascoux-Combe C; Sogni P; Rey D; Barthe Y; Pol S; Cacoub P; Zoulim F; Piroth L
    J Hepatol; 2014 Oct; 61(4):761-9. PubMed ID: 24882048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.
    Audsley J; Bent SJ; Littlejohn M; Avihingsanon A; Matthews G; Bowden S; Bayliss J; Luciani F; Yuen L; Fairley CK; Locarnini S; Lewin SR; Sasadeusz J
    AIDS; 2016 Jun; 30(10):1597-606. PubMed ID: 26950313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
    Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
    J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil.
    Mendes-Correa MC; Pinho JR; Gomes-Gouvea MS; da Silva AC; Guastini CF; Martins LG; Leite AG; Silva MH; Gianini RJ; Uip DE
    BMC Infect Dis; 2011 Sep; 11():247. PubMed ID: 21933423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
    Lewin SR; Ribeiro RM; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini SA; Ruxrungtham K; Perelson AS; Dore GJ
    Hepatology; 2009 Apr; 49(4):1113-21. PubMed ID: 19115219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
    Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ
    Hepatology; 2008 Oct; 48(4):1062-9. PubMed ID: 18697216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensification of treatment with pegylated interferon alfa in patients coinfected with HIV and HBV genotype H or G being treated with a tenofovir/emtricitabine-containing regimen.
    Mata-Marín JA; Mata-Marín LA; Arroyo-Anduiza CI; Huerta-García G; Sandoval-Ramirez JL; Manjarrez-Tellez B; Gaytán-Martínez JE
    Hepatogastroenterology; 2014; 61(133):1187-91. PubMed ID: 25436280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.
    Kang M; Hollabaugh K; Pham V; Koletar SL; Wu K; Smurzynski M; Aberg JA
    J Acquir Immune Defic Syndr; 2014 Jun; 66(2):172-80. PubMed ID: 24694927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort.
    Kim HN; Rodriguez CV; Van Rompaey S; Eron JJ; Thio CL; Crane HM; Overton ET; Saag MS; Martin J; Geng E; Mugavero M; Rodriguez B; Mathews WC; Boswell S; Moore R; Kitahata MM;
    J Acquir Immune Defic Syndr; 2014 May; 66(1):96-101. PubMed ID: 24500175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression.
    Huang AJ; Núñez M
    J Int Assoc Provid AIDS Care; 2015; 14(4):360-8. PubMed ID: 25999329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
    Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
    J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
    Menne S; Butler SD; George AL; Tochkov IA; Zhu Y; Xiong S; Gerin JL; Cote PJ; Tennant BC
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3617-32. PubMed ID: 18676881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.
    Childs K; Joshi D; Byrne R; Bruce M; Carey I; Agarwal K; Taylor C
    AIDS; 2013 Jun; 27(9):1443-8. PubMed ID: 23435302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
    Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
    J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B.
    Plaza Z; Aguilera A; Mena A; Vispo E; Sierra-Enguita R; Tomé S; Pedreira J; Rodriguez C; Barreiro P; del Romero J; Soriano V; Poveda E
    AIDS; 2013 Sep; 27(14):2219-24. PubMed ID: 23669158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.
    Lacombe K; Gozlan J; Boelle PY; Serfaty L; Zoulim F; Valleron AJ; Girard PM
    AIDS; 2005 Jun; 19(9):907-15. PubMed ID: 15905671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.
    Avihingsanon A; Lewin SR; Kerr S; Chang JJ; Piyawat K; Napissanant N; Matthews GV; Dore GJ; Bowden S; Lange J; Ruxrungtham K
    Antivir Ther; 2010; 15(6):917-22. PubMed ID: 20834105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.
    Li Y; Xie J; Han Y; Wang H; Zhu T; Wang N; Lv W; Guo F; Qiu Z; Li Y; Du S; Song X; Thio CL; Li T
    J Acquir Immune Defic Syndr; 2016 May; 72(1):39-45. PubMed ID: 26745828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.